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Introduction
The NVT Allegra transcatheter heart valve (NVT) (New Valve 
Technology, Hechingen, Germany) received CE-mark approval in 
March 2017. The valve is composed of a self-expanding, nitinol 
stent frame with a sewn-in supra-annular bovine pericardial heart 
valve1. Currently, there are three sizes (23 mm, 27 mm, and 
31 mm) available, all delivered through an 18 Fr sheath.
Methods
Prospectively collected data between April 2017 and January 2018 
from five European centres in Spain and Switzerland were ana-
lysed. All patients gave informed consent for the procedure and 
for data collection, according to the regulations of the respective 
local ethics committees.
PATIENT SELECTION
All patients deemed candidates for transcatheter aortic valve 
implantation (TAVI) by the local Heart Team and treated with the 
Allegra valve2 were included in this study. Endpoints were defined 
according to the VARC-2 criteria3.
STATISTICAL ANALYSIS
Statistical analyses were performed using SPSS, Version 23 (IBM 
Corp., Armonk, NY, USA). Continuous values were expressed 
as mean and standard deviation (SD). Categorical values were 
expressed as proportions of the total. Between-group compari-
sons were performed using a paired Student’s t-test, or Wilcoxon 
test. A two-tailed p-value of <0.05 was considered statistically 
significant.
DEVICE SPECIFICATIONS
The Allegra valve has a self-expanding nitinol stent frame with 
a supra-annular bovine pericardial valve. The specific design of 
the stent frame with variable radial forces along the stent, a con-
cave stent shape and tip deflection during diastole aims at remov-
ing leaflet stress by up to 40% (according to the manufacturer’s 
preclinical study data), which may potentially enhance durability.
The valve is currently available in three different sizes (23 mm, 
27 mm, and 31 mm), which are all delivered through a commer-
cially available 18 Fr sheath. A sealing skirt of 12 mm at the ventri-
cular part of the valve minimises the risk of paravalvular leaks.
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The handle of the delivery system allows a stepwise, controlled 
release of the valve with stable haemodynamics throughout deploy-
ment without any flow obstruction. By repetitively squeezing the 
handle, the middle part of the valve stent starts bulging, allow-
ing the leaflet tips to move within the stent frame (“Permaflow”). 
The lower marker is then aligned with the aortic annulus at the 
non-coronary cusp and tension on the delivery system is released 
(no forward push). The entire ventricular part of the valve is 
quickly deployed by squeezing the release knob. No rapid pacing 
is required; however, fast pacing at a rate of 100-140/min may be 
utilised if a large pulse pressure is present. At this stage, the valve 
is potentially fully retrievable by externalising the valve through 
the sheath and reinserting after re-crimping.
Once a satisfactory position is confirmed, the aortic part of 
the valve stent frame is released by using the handle to complete 
implantation.
PROCEDURE
The procedures were performed under local or general anaesthe-
sia, according to the local institutional practice.
POST-PROCEDURAL FOLLOW-UP
Dual antiplatelet therapy with lifelong acetylsalicylic acid 
and three to six months of clopidogrel was routine, unless the 
patient had an indication for oral anticoagulation. Transthoracic 
echocardiography was performed before discharge and at 30 days.
Results
PATIENT RESULTS
Fifty-nine patients (mean age 78±8 years, 37% male, mean STS-
PROM score 5.2±4.2) were included.
PROCEDURAL OUTCOMES
Balloon predilatation was performed in 82% of the cases. Post-
dilatation was performed in 36% of patients due to malapposi-
tion, excessive paravalvular leak (PVL) or both. Device success 
was 95% and 30-day mortality was 1.7%. No stroke or major/life-
threatening bleeding occurred. The rate of major vascular compli-
cations was 3.4% (Table 1).
There was one periprocedural death. A polymorbid patient with 
severely reduced right ventricular function suffered from severe 
hypotension requiring mechanical resuscitation after insertion of 
the delivery sheath. Association with severe bradycardia made 
severe bleeding improbable. Despite fast and successful implanta-
tion of the Allegra valve, the patient did not recover and died in 
the catheterisation laboratory.
Acute kidney injury occurred in four patients (6.8%) and 
resolved in all patients before discharge.
The pacemaker implantation rate was 13.5% at 30 days.
VALVE PERFORMANCE RESULTS
Haemodynamic outcomes showed a mean gradient of 
7.2±3.5 mmHg with an effective orifice area (EOA) of 
2.06±0.3 cm2. Valve performance remained stable at 30 days. 
More than mild paravalvular leak was present in 5.1% of patients 
before discharge and 3.4% at 30 days.
PATIENT STATUS
At baseline, most patients suffered from NYHA Class III or IV 
symptoms. A significant improvement occurred at discharge and 
at 30 days (p<0.01). At 30 days >95% of patients were in NYHA 
Class I or II (Figure 1).
Discussion
This multicentre European registry demonstrates good short-term 
haemodynamic outcomes with the novel Allegra transcatheter heart 
valve with low transvalvular gradients, a large EOA (>2 cm2) and 
low PVL rates (more than mild PVL in 3.4% of patients). Device 
success was 95%, comparable with other valves on the market.
In summary, in our real-world experience, the Allegra yielded 
good short-term outcomes.
Table 1. Procedural and 30-day outcomes.
Device success (56/59) 95%
Early safety (at 30 days)
All-cause mortality* (1/59) 1.7%
All stroke (disabling and non-disabling) (0/59) 0%
Life-threatening bleeding (0/59) 0%
Acute kidney injury (4/59) 6.8%
Coronary artery obstruction requiring 
intervention (1/59) 1.7%
Major vascular complication (2/59) 3.4%
Valve-related dysfunction requiring repeat 
procedure (0/59) 0%
Clinical efficacy (after 30 days)
All-cause mortality* (1/59) 1.7%
All stroke (disabling and non-disabling) (0/59) 0%
Requiring hospitalisation for valve-related 
symptoms or worsening congestive heart 
failure
(0/59) 0%
NYHA Class III or IV (2/59) 3%
Valve-related dysfunction (0/59) 0%
Time-related valve safety
Structural valve deterioration (0/59) 0%
Valve-related dysfunction (0/59) 0%
Requiring repeat procedure (0/59) 0%
Prosthetic valve endocarditis (0/59) 0%
Prosthetic valve thrombosis (0/59) 0%
Thromboembolic events (0/59) 0%
VARC bleeding, unless clearly unrelated to 
valve therapy (0/59) 0%
New pacemaker implantation (8/59) 13.5%
*Patient died before attempted NVT implantation. All definitions 
according to the Valve Academic Research Consortium-2 consensus 
document.
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NVT Allegra multicentre experience
Limitations
The current study is observational and limited by the low patient 
numbers. Larger studies are needed.
Conclusion
The Allegra transcatheter, self-expanding valve is safe and effec-
tive in the treatment of high- and intermediate-risk patients with 
severe aortic stenosis.
Impact on daily practice
Our results show that transcatheter aortic valve implantation 
using the NVT Allegra valve results in good haemodynamic 
outcomes and a low complication rate.
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Figure 1. Functional capacity - NYHA grade at baseline, discharge 
and 30 days. Baseline vs. Discharge, p<0.01; Baseline vs. 30 days, 
p<0.01; Discharge vs. 30 days, p=NS.
